Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
07 Maio 2024 - 9:00AM
Business Wire
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced its achievement of surpassing a
significant milestone of 500 peer-reviewed publications featuring
its technology in esteemed scientific journals. This milestone
highlights Guardant Health’s leadership, amassing one of the most
robust portfolios of relevant liquid biopsy research studies in the
industry.
These publications have profoundly impacted the oncology field,
including validating Companion Diagnostic (CDx) claims, driving
changes in the National Comprehensive Cancer Network (NCCN)
guidelines for liquid biopsy, and providing essential clinical
outcomes data. This includes publications across multiple cancers,
including 189 in lung cancer, 53 in breast cancer, and 51 in
colorectal cancer, continuing the company’s approach of starting
with lung cancer and expanding its product portfolio into other
diseases.
“We have partnered with thousands of authors representing
diverse perspectives and expertise worldwide,” said Dr. Craig
Eagle, chief medical officer at Guardant Health. “We accelerated
our publication rate over the past two years, averaging
approximately 100 publications annually, with some of the brightest
minds in the scientific community.”
Publications include notable collaborations with 45 National
Cancer Institute (NCI)-Designated Cancer Centers, underlining the
trust and confidence of Guardant Health in cancer research.
“High-quality science has always been the driving force in our
mission to conquer cancer with data,” said Helmy Eltoukhy, Guardant
Health chairman and co-CEO. “We are proud to have collaborated with
leading scientists over the past 12 years to conduct some of the
largest and most impactful studies ever to be performed in our
field. This incredible breadth of clinical data demonstrates the
real-world impact of our technology on patient outcomes, advances
the clinical utility and value of our tests, and helps to improve
payer coverage and patient access.”
About Guardant Health
Guardant Health is a leading precision medicine company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240507852378/en/
Investor Contact: investors@guardanthealth.com
Media Contact: Melissa Marasco press@guardanthealth.com
+1 650-647-3711
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024